Nix Nancy M, Price Allyson
Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas.
J Adv Pract Oncol. 2019 Nov-Dec;10(Suppl 4):9-18. doi: 10.6004/jadpro.2019.10.8.13. Epub 2019 Nov 1.
Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews the mechanisms of action, indications, and clinical trial details for eight novel agents, as well as the current discussions surrounding monitoring minimal residual disease.
直到最近，自20世纪70年代以来，急性髓系白血病（AML）的治疗进展一直缓慢。然而，在过去几年中，随着对AML病理生理学的认识不断深入，美国食品药品监督管理局已批准了多种治疗方法。本文回顾了八种新型药物的作用机制、适应证和临床试验细节，以及目前围绕监测微小残留病的讨论。
